
==== Front
Biochip J
Biochip J
Biochip Journal
1976-0280 2092-7843 The Korean BioChip Society (KBCS) Seoul 

4106
10.1007/s13206-020-4106-6
Review Article
Multiscale Biofluidic and Nanobiotechnology Approaches for Treating Sepsis in Extracorporeal Circuits
https://orcid.org/0000-0001-9636-3209Kang Joo H. jookang@unist.ac.kr  grid.42687.3f0000 0004 0381 814XDepartment of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), 50, UNIST-gil, Ulsan, 44919 Republic of Korea 
12 3 2020 
1 9
12 2 2020 1 3 2020 © The Korean BioChip Society and Springer 2020This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Infectious diseases and their pandemics periodically attract public interests due to difficulty in treating the patients and the consequent high mortality. Sepsis caused by an imbalanced systemic inflammatory response to infection often leads to organ failure and death. The current therapeutic intervention mainly includes “the sepsis bundles,” antibiotics (antibacterial, antiviral, and antifungal), intravenous fluids for resuscitation, and surgery, which have significantly improved the clinical outcomes in past decades; however, the patients with fulminant sepsis are still in desperate need of alternative therapeutic approaches. One of the potential supportive therapies, extracorporeal blood treatment, has emerged and been developed for improving the current therapeutic efficacy. Here, I overview how the treatment of infectious diseases has been assisted with the extracorporeal adjuvant therapy and the potential utility of various nanobiotechnology and microfluidic approaches for developing new auxiliary therapeutic methods.

Keywords
MicrofluidicsNanobiotechnologyExtracorporeal devicesInfectious diseasesBlood treatmentSepsis
==== Body
Acknowledgements
This work was supported by a grant funded by Samsung Research Funding and Incubation Center for Future Technology (SRFC-IT16 02-02), and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (Grant No. NRF-2019R1C1C1006124).

Conflict of Interests The authors declare no competing financial interests.
==== Refs
References
1. Levy MM  Evans LE  Rhodes A   The surviving sepsis campaign bundle: 2018 update Intensive Care Med. 2018 44 925 928 10.1007/s00134-018-5085-0 29675566 
2. Gary T  Mingle D  Yenamandra A   The evolving definition of sepsis Int. Clin. Pathol. J. 2016 2 154 159 
3. Bone RC  Balk RA  Cerra FB  Dellinger RP  Fein AM  Knaus WA  Schein R  Sibbald W J   Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine CHEST Journal 1992 101 1644 1655 10.1378/chest.101.6.1644 
4. Rittirsch D  Flierl MA  Ward PA   Harmful molecular mechanisms in sepsis Nat. Rev. Immunol. 2008 8 776 787 10.1038/nri2402 18802444 
5. Baron RM  Baron MJ  Perrella MA   Pathobiology of Sepsis: Are We Still Asking the Same Questions? Am. J. Respir. Cell Mol. Biol. 2006 34 129 134 10.1165/rcmb.F308 16421210 
6. Hernandez Botero Johan Sebastian  Florian Perez Maria Cristina   The History of Sepsis from Ancient Egypt to the XIX Century Sepsis - An Ongoing and Significant Challenge 2012 
7. Abraham E  Laterre P-F  Garg R  Levy H  Talwar D  Trzaskoma BL  François B  Guy JS  Brückmann M  Rea-Neto Á  Rossaint R  Perrotin D  Sablotzki A  Arkins N  Utterback BG  Macias WL   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N. Engl. J. Med. 2005 353 1332 1341 10.1056/NEJMoa050935 16192478 
8. Ranieri VM  Thompson BT  Barie PS  Dhainaut JF  Douglas IS  Finfer S  Gårdlund B  Marshall JC  Rhodes A  Artigas A   Drotrecogin alfa (activated) in adults with septic shock N. Engl. J. Med. 2012 366 2055 2064 10.1056/NEJMoa1202290 22616830 
9. FDA Drug Safety Communication: Voluntary market withdrawal of Xigris [drotrecogin alfa (activated)] due to failure to show a survival benefit (https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-voluntary-market-withdrawal-xigris-drotrecogin-alfa-activated-due).
10. Peiris JSM  Yuen KY  Osterhaus ADME  Stöhr K   The Severe Acute Respiratory Syndrome N. Engl. J. Med. 2003 349 2431 2441 10.1056/NEJMra032498 14681510 
11. Ilunga Kalenga O  Moeti M  Sparrow A  Nguyen V-K  Lucey D  Ghebreyesus TA   The ongoing Ebola epidemic in the Democratic Republic of Congo, 2018–2019 N. Engl. J. Med 2019 381 373 383 10.1056/NEJMsr1904253 31141654 
12. Arabi YM  Balkhy HH  Hayden FG  Bouchama A  Luke T  Baillie JK  Al-Omari A  Hajeer AH  Senga M  Denison MR  Nguyen-Van-Tam JS  Shindo N  Bermingham A  Chappell JD  van Kerkhove MD  Fowler RA   Middle East respiratory syndrome N. Engl. J. Med 2017 376 584 594 10.1056/NEJMsr1408795 28177862 
13. Chuang Y-C  Chang S-C  Wang W-K   High and increasing Oxa-51 DNA load predict mortality in Acinetobacter baumannii bacteremia: implication for pathogenesis and evaluation of therapy PLoS ONE 2010 5 e14133 10.1371/journal.pone.0014133 21152436 
14. Towner JS  Rollin PE  Bausch DG  Sanchez A  Crary SM  Vincent M  Lee WF  Spiropoulou CF  Ksiazek TG  Lukwiya M  Kaducu F  Downing R  Nichol ST   Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome J. Virol. 2004 78 4330 4341 10.1128/JVI.78.8.4330-4341.2004 15047846 
15. Chung H  Lee JH  Jo YH  Hwang JE  Kim J   Circulating monocyte counts and its impact on outcomes in patients with severe sepsis including septic shock SHOCK 2019 51 423 429 10.1097/SHK.0000000000001193 30286035 
16. Monard C  Rimmelé T  Ronco C   Extracorporeal blood purification therapies for sepsis Blood Purif. 2019 47 1 14 10.1159/000499520 30982028 
17. Shoji H   Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin) Ther. Apheresis Dial. 2003 7 108 114 10.1046/j.1526-0968.2003.00005.x 
18. Didar TF  Cartwright MJ  Rottman M  Graveline AR  Gamini N  Watters AL  Leslie DC  Mammoto T  Rodas MJ  Kang JH  Waterhouse A  Seiler BT  Lombardo P  Qendro EI  Super M  Ingber DE   Improved treatment of systemic blood infections using antibiotics with extracorporeal opsonin hemoadsorption Biomaterials 2015 67 382 392 10.1016/j.biomaterials.2015.07.046 26253638 
19. Kang JH  Um E  Diaz A  Driscoll H  Rodas M J  Domansky K  Watters AL  Super M  Stone HA  Ingber DE   Optimization of pathogen capture in flowing fluids with magnetic nanoparticles Small 2015 11 5657 5666 10.1002/smll.201501820 26389806 
20. Cytosorbents-How it works, https://www.mddionline.com/file/cytosorbents-how-it-worksjpg.
21. Herrmann IK  Schlegel AA  Graf R  Stark WJ  Beck-Schimmer B   Magnetic separation-based blood purification: a promising new approach for the removal of disease-causing compounds? J. Nano-biotechnol 2015 13 49 
22. Herrmann IK  Urner M  Koehler FM  Hasler M  Roth-Z’Graggen B  Grass RN  Ziegler U  Beck-Schimmer B  Stark WJ   Blood purification using functionalized core/shell nanomagnets Small 2010 6 1388 1392 10.1002/smll.201000438 20564487 
23. Kang JH  Super M  Yung CW  Cooper RM  Domansky K  Graveline AR  Mammoto T  Berthet JB  Tobin H  Cartwright MJ  Watters A L  Rottman M  Waterhouse A  Mammoto A  Gamini N  Rodas MJ  Kole A  Jiang A  Valentin TM  Diaz A  Takahashi K  Ingber D E   An extracorporeal blood-cleansing device for sepsis therapy Nat. Med. 2014 20 1211 1216 10.1038/nm.3640 25216635 
24. Cole L  Bellomo R  Hart G  Journois D  Davenport P  Tipping P  Ronco C   A phase II randomized, controlled trial of continuous hemofiltration in sepsis Crit. Care Med. 2002 30 100 106 10.1097/00003246-200201000-00016 11902250 
25. Kellum JA  Dishart MK   Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats Crit. Care 2002 6 429 433 10.1186/cc1528 12398783 
26. Song M  Winchester J  Albright RL  Capponi VJ  Choquette MD  Kellum JA   Cytokine removal with a novel adsorbent polymer Blood Purif. 2004 22 428 434 10.1159/000080235 15316198 
27. DiLeo MV  Kellum JA  Federspiel WJ   A simple mathematical model of cytokine capture using a hemoadsorption device Ann. Biomed. Eng. 2009 37 222 229 10.1007/s10439-008-9587-8 18949559 
28. Young, W.-T., Albright, R.L., Golobish, T.D., Capponi, V. & Chan, P. Size- selective polymer system, US 8211310 B2.
29. Shukla AM   Extracorporeal therapy in sepsis: are we there yet? Kidney Int. 2012 81 336 338 10.1038/ki.2011.375 22289793 
30. Oh S  Jung H  Seo H  Min M-K  Kim B  Hahn YK  Kang JH  Choi S   Magnetic activated cell sorting (MACS) pipette tip for immunomagnetic bacteria separation Sens. Actuators, B 2018 272 324 330 10.1016/j.snb.2018.05.146 
31. Wilson S  Lane A  Rosedale R  Stanley C   Concentration of Mycobacterium tuberculosis from sputum using ligand-coated magnetic beads Int. J. Tuberc. Lung. Dis. 2010 14 1164 1168 20819263 
32. Kang JH  Krause S  Tobin H  Mammoto A  Kanapathipillai M  Ingber DE   A combined micromagnetic-microfluidic device for rapid capture and culture of rare circulating tumor cells Lab Chip 2012 12 2175 2181 10.1039/c2lc40072c 22453808 
33. Song S-H  Lee JH  Yoon J  Park W   Functional microparticle R&D for IVD and cell therapeutic technology: Large-scale commercialized products BioChip J. 2019 13 95 104 10.1007/s13206-019-3107-9 
34. Kang JH  Park J-K   Magnetophoretic continuous purification of single-walled carbon nanotubes from catalytic impurities in a microfluidic device Small 2007 3 1784 1791 10.1002/smll.200700334 17890645 
35. Sari AY  Eko AS  Candra K  Hasibuan DP  Ginting M  Sebayang P  Simamora P   Synthesis, properties and application of glucose coated Fe3 O4  nanoparticles prepared by co-precipitation method IOP Conf. Ser.: Mater. Sci. Eng. 2017 214 012021 10.1088/1757-899X/214/1/012021 
36. Scott K.   INTRODUCTION TO MEMBRANE SEPARATIONS Handbook of Industrial Membranes 1995 3 185 
37. Xia N  Hunt T  Mayers B  Alsberg E  Whitesides G  Westervelt R  Ingber D   Combined microfluidic-micromagnetic separation of living cells in continuous flow Biomed. Microdevices 2006 8 299 308 10.1007/s10544-006-0033-0 17003962 
38. Yung CW  Fiering J  Mueller AJ  Ingber DE   Micromagnetic-microfluidic blood cleansing device Lab Chip 2009 9 1171 1177 10.1039/b816986a 19370233 
39. Lee Jung-Jae  Jeong Kyung Jae  Hashimoto Michinao  Kwon Albert H.  Rwei Alina  Shankarappa Sahadev A.  Tsui Jonathan H.  Kohane Daniel S.   Synthetic Ligand-Coated Magnetic Nanoparticles for Microfluidic Bacterial Separation from Blood Nano Letters 2013 14 1 1 5 10.1021/nl3047305 23367876 
40. Microfluidic magnetic particle sorting and separation: a short review. https://www.elveflow.com/microfluidic-tutorials/microfluidic-reviews-and-tutorials/magnetic-particle-separation-a-short-review/.
41. Kang JH  Driscoll H  Super M  Ingber DE   Application of a Halbach magnetic array for longrange cell and particle separations in biological samples Appl. Phys. Lett. 2016 108 213702 10.1063/1.4952612 
42. Inglis DW  Riehn R  Austin RH  Sturm JC   Continuous microfluidic immunomagnetic cell separation Appl. Phys. Lett. 2004 85 5093 5095 10.1063/1.1823015 
43. Jung SH  Hahn YK  Oh S  Kwon S  Um E  Choi S  Kang JH   Advection flows-enhanced magnetic separation for high-throughput bacteria separation from undiluted whole blood Small 2018 14 e1801731 10.1002/smll.201801731 30044534 
44. Chung AJ   A minireview on inertial microfluidics fundamentals: Inertial particle focusing and secondary Ffow BioChip J. 2019 13 53 63 10.1007/s13206-019-3110-1 
45. Choi S  Park J-K   Continuous hydrophoretic separation and sizing of microparticles using slanted obstacles in a microchannel Lab Chip 2007 7 890 897 10.1039/b701227f 17594009 
46. Chang T  Tu Y-K  Lee C-T  Chao A  Huang C-H  Wang M-J  Yeh Y-C   Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: A systemic review, meta-analysis update, and disease severity subgroup meta-analysis Crit. Care Med. 2017 45 e858 e864 10.1097/CCM.0000000000002362 28445237 
47. Klein DJ  Foster D  Walker PM  Bagshaw SM  Mekonnen H  Antonelli M   Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial Intensive Care Med. 2018 44 2205 2212 10.1007/s00134-018-5463-7 30470853 
48. Hemotune. https://www.hemotune.ch/.
49. BOA Biomedical Inc. https://otd.harvard.edu/news/new-startup-boa-biomedical-launches-to-reduce-sepsis-deaths.
50. Romaschin AD  Klein DJ  Marshall JC   Bench-to-bedside review: Clinical experience with the endotoxin activity assay Crit. Care 2012 16 248 10.1186/cc11495 23206992 
51. Salter SJ  Cox MJ  Turek EM  Calus ST  Cookson WO  Moffatt MF  Turner P  Parkhill J  Loman NJ  Walker AW   Reagent and laboratory contamination can critically impact sequence-based microbiome analyses BMC Biol. 2014 12 87 10.1186/s12915-014-0087-z 25387460 
52. Kim S  Masum F  Jeon JS   Recent developments of chip-based phenotypic antibiotic susceptibility testing BioChip J. 2019 13 43 52 10.1007/s13206-019-3109-7 
53. Herrmann IK  Beck-Schimmer B  Schumacher CM  Gschwind S  Kaech A  Ziegler U  Clavien P-A  Günther D  Stark WJ  Graf R  Schlegel AA   In vivo risk evaluation of carbon-coated iron carbide nanoparticles based on short- and long-term exposure scenarios Nanomedicine 2016 11 783 796 10.2217/nnm.16.22 26979124 
54. Jang BH  Kwon S  Kang JH   Measurement of the magnetic susceptibility of subtle paramagnetic solutions using the diamagnetic repulsion of polymer microparticles Lab Chip 2019 19 2356 2361 10.1039/C9LC00245F 31173624 
55. Bougas L  Langenegger LD  Mora CA  Zeltner M  Stark WJ  Wickenbrock A  Blanchard JW  Budker D   Nondestructive in-line sub-picomolar detection of magnetic nanoparticles in flowing complex fluids Sci. Rep. 2018 8 3491 10.1038/s41598-018-21802-2 29472727 
56. Shahidi Bonjar, A.H. Antiviral therapy: a perspective. Drug Des., Dev. Ther. DOI 10.2147/DDDT.S83037 (2016).
57. Park I  Lee JH  Jang D-H  Kim D  Chang H  Kwon H  Kim S  Kim TS  Jo YH   Characterization of fecal peritonitis-induced sepsis in a porcine model J. Surg. Res. 2019 244 492 501 10.1016/j.jss.2019.06.094 31330293 
58. Fink MP   Animal models of sepsis Virulence 2014 5 143 153 10.4161/viru.26083 24022070 
59. Pino CJ  Yevzlin AS  Tumlin J  Humes HD   Cell-based strategies for the treatment of kidney dysfunction: a review Blood Purif. 2012 34 117 123 10.1159/000341649 23095410 
60. Huang CY  Daniels R  Lembo A  Hartog C  O’Brien J  Heymann T  Reinhart K  Nguyen H B  Sepsis Survivors Engagement Project SSEP  Life after sepsis: an international survey of survivors to understand the post-sepsis syndrome Int. J. Qual. Health Care 2019 31 191 198 10.1093/intqhc/mzy137 29924325

